Hence, CB1 antagonism has been proposed as a promising target to treat cachexia and sarcopenia through modulation of the metabolism and muscle regenerative capacity [39], and more recently as an add-on therapy in DMD which could decrease the usage of steroidal anti-inflammatory drugs, presenting serious side effects. This evidence concerns the gene CNR1 and sarcopenia.